Diabetes Drugs Ref
iOS app by ATIF ELNIL. Medical · ATIF ELNIL
- Store rating
- 0 / 5
- Store rating count
- 0
- Download price
- Free to download
- In-app purchases
- Unknown
- Version
- 1.0.1
- Listing last refreshed
- 2026-09-10
View the original store listing
Store description excerpt
Diabetes Drugs Reference — evidence-based pharmacology reference for diabetes drug classes. Based on NICE NG28 2022, ADA Standards of Care 2024, and SIGN 154. FREE — no purchase needed: — SGLT2 Inhibitors: empagliflozin, dapagliflozin, canagliflozin, ertugliflozin with doses, CV outcomes and renal thresholds FULL ACCESS — £14.99/year unlocks: — GLP-1 Receptor Agonists: semaglutide, liraglutide, dulaglutide, tirzepatide — DPP-4 Inhibitors: sitagliptin, linagliptin, alogliptin, vildagliptin — Metformin: doses, eGFR thresholds, B12 monitoring — Sulfonylureas: gliclazide, glipizide, glibenclamide — Insulin: basal, bolus, premixed, ultra-long analogues — Thiazolidinediones, Meglitinides, Alpha-glucosidase inhibitors — Prescribing Guide: renal dosing table, contraindications, monitoring — HbA1c Targets: individualised targets by patient group — CV Outcomes Trials: EMPA-REG, LEADER, DECLARE, DAPA-HF, REWIND, SURPASS — Hypoglycaemia Management: severity grading, treatment protocol — Sick Day Rules: SADMAN, JBDS inpatient protocol — Special Situations: pregnancy, CKD, elderly, perioperative — References: 25+ tappable citations, NICE, NEJM, Lancet, ADA Subscription renews automatically at £14.99/year unless cancelled at least 24 hours before the end of the current period. Manage in App Store Settings > Subscriptions. For use by qualified healthcare professionals only. Always verify doses against the current BNF and SmPC before prescribing.
Review coverage
AppRill has captured 0 reviews for this app. This is a collected sample, separate from the store rating count. Latest review capture: Not captured yet.
Recent captured chart positions
No chart positions have been captured for this app yet.
Chart position, rating count and review coverage do not establish downloads, revenue or profit. Understand the differences.